Gallbladder Cancer Foundation

What Gallbladder Cancer Foundation does

The Gallbladder Cancer Foundation is a 501(c)(3) public charity (EIN 99-0724671) founded in January 2024 by Sanjeev Kumar and publicly launched in February 2025. It is the first and only US nonprofit dedicated specifically to gallbladder cancer, a rare and aggressive disease affecting approximately 5,000 people in the United States and 122,000 people worldwide annually, with most cases diagnosed at advanced stages. The organization is headquartered at a mailing address in Springfield, Ohio, operates without a physical office, runs on a volunteer model with a $0 CEO salary, and has achieved GuideStar (Candid) Platinum Level of Transparency.

The foundation's core offering is a centralized hub of free services for newly diagnosed gallbladder cancer patients, caregivers, and the bereaved. Functional services include three monthly Zoom-based support groups (patient, caregiver, bereaved), distribution of NCCN and ESMO patient guidelines, biomarker testing guidance, specialist referral pathways to institutions such as UCSF and Ohio State's James Cancer Center, and navigation to copay assistance programs including The Assistance Fund, the PAN Foundation, and AstraZeneca's AZ&Me Prescription Savings Program. The foundation also conducts a Genome-Wide Association Study (GWAS) in partnership with Mayo Clinic to identify genomic risk factors for the disease.

The technology stack is partnership-mediated rather than proprietary. The flagship product, AI Advocate for Gallbladder Cancer, is delivered through a partnership with Citizen Health and provides patients with AI-driven medical record aggregation, AI-generated answers from health history, and biomarker-based clinical trial matching. Clinical trial matching is further enabled via Biomarker Help, and international patients are routed to peer organizations in the UK (AMMF), Spain (ATUVIBI), Australia/New Zealand, and India (Jarurat Care). Revenue is derived entirely from charitable contributions — individual donations, corporate matching gifts, corporate sponsorships, donor-advised funds, IRA qualified charitable distributions, stock and crypto donations, Facebook Fundraisers, and a $50,000 peer-to-peer campaign via GiveWP — with the top single donor to date at $5,000 and most gifts ranging from $10 to several hundred dollars.

Name

Gallbladder Cancer Foundation

Legal name

Gallbladder Cancer Foundation

Website

https://gallbladdercancer.org

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

The Gallbladder Cancer Foundation is a US 501(c)(3) public charity and the only US nonprofit dedicated specifically to gallbladder cancer, providing free support groups, patient education, clinical trial navigation, and an AI-powered medical record platform to patients, caregivers, and the bereaved.

Ownership category

akta.pro rank

Product category

Cancer Patient Advocacy Services

NAICS

Voluntary Health Organizations (813212), Grantmaking Foundations (813211)

SIC

Services-Health Services (8000), Services-Social Services (8300)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Cancer patient support
• Patient advocacy services
• Cancer education resources
• Clinical trial matching
• Rare cancer research

Headquarters

HQ city

Springfield

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Operations, Marketing or Sales, Technology or R&D, Personnel, Others

Revenue model

1. Individual Donations: One-time and recurring online donations via the GiveWP platform. The peer-to-peer fundraising campaign enables supporters to create teams and raise funds for the organization. Facebook Fundraisers allow donors to create birthday or commemorative fundraisers. The peer-to-peer campaign objective is set at $50,000 to begin funding gallbladder cancer research grants.
2. Corporate Matching Gifts: The organization encourages donors to check with their employers for matching gift programs, multiplying the impact of individual donations.
3. Corporate Sponsorships: Companies that share the organization's values can become corporate or industry sponsors. Industry/corporate partnerships are handled via a dedicated email address ([email protected]).
4. Donor-Advised Fund & IRA Donations: Accepts donations through donor-advised funds (partner: Charityvest.org) and Qualified Charitable Distributions from IRAs (up to $100,000 tax-free per the IRS). Also accepts stock and cryptocurrency donations.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

The Gallbladder Cancer Foundation is a 501(c)(3) public charity that delivers free patient advocacy services for people affected by gallbladder cancer, including virtual peer support groups, centralized educational resources, and referrals to financial assistance programs. The foundation operates an AI-powered patient medical record tool (in partnership with Citizen Health), facilitates biomarker-driven clinical trial matching (via Biomarker Help), and runs a GWAS genetic study with Mayo Clinic. It also raises charitable donations to fund the first gallbladder cancer research grants.

Product overview

The Gallbladder Cancer Foundation is a 501(c)(3) nonprofit patient advocacy organization that provides resources, support, and educational information for gallbladder cancer patients and caregivers. The organization's primary offering is its website and partnered platforms. The main product is the AI Advocate for Gallbladder Cancer (built in partnership with Citizen Health), which serves as a centralized patient data management platform. The organization also provides virtual support groups, patient education resources, biomarker testing guidance, genetic study participation opportunities, and connections to clinical trials and financial assistance programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Virtual Support Groups
• AI Advocate for Gallbladder Cancer
• Biomarker Help Clinical Trial Matching
• GWAS Genetic Study Enrollment

Quantifiable outcome

• ~5,000 new gallbladder cancer patients per year in the US have access to a dedicated support and resource organization for the first time
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

17 partnerships are on record, tiered core and supporting.

• Citizen HealthcoreStrategic or Co-development PartnerThe Gallbladder Cancer Foundation partnered with Citizen Health to launch the AI Advocate for Gallbladder Cancer, a free, secure, personalized platform that empowers patients to centralize medical records from multiple health systems, get AI-generated answers from their records, decode medical jargon, generate summaries for appointments, record doctor visits, and match to clinical trials based on biomarkers. Participation is 100% free, private, and includes an option to share de-identified data to advance research.
• Biomarker HelpcoreStrategic or Co-development PartnerBiomarker Help, founded by Matt Reidy (a cholangiocarcinoma survivor), provides a free service that matches cancer patients to personalized clinical trials and targeted therapies based on their specific biomarker profiles. Patients can upload biomarker reports or enter mutations manually. The platform includes an interactive clinical trial map and sends email alerts when new matching trials become available. The foundation actively refers patients to this service.
• The Assistance FundcoreOthersThe Assistance Fund (TAF) provides copay assistance to patients with biliary tract cancer, covering treatment costs for qualifying patients. The Gallbladder Cancer Foundation references TAF as a key resource for patients needing financial support. In at least one documented case, TAF covered a $2,486.10 copay bill for a gallbladder cancer patient's durvalumab treatment. TAF opens enrollment periodically (first-come, first-served) and also has a waitlist option.
• PAN FoundationsupportingOthersThe PAN Foundation provides copay assistance to patients with biliary tract cancer. The Gallbladder Cancer Foundation includes PAN Foundation as a referenced resource for patients needing help covering treatment costs. Like TAF, enrollment periods are limited and dependent on fund availability.
• National Comprehensive Cancer Network (NCCN)supportingOthersThe NCCN provides evidence-based clinical guidelines for cancer treatment. The foundation hosts links to NCCN patient guidelines for gallbladder and bile duct cancers (also available in Spanish), as well as supportive care guidelines covering anemia, neutropenia, blood clots, fatigue, nausea, immunotherapy side effects, palliative care, and survivorship care. The foundation recommends all newly diagnosed patients download and read these documents.
• European Society for Medical Oncology (ESMO)supportingOthersESMO provides patient guides for biliary tract cancer and immunotherapy side effects (available in multiple languages including Spanish, German, French, Italian, Portuguese, and others). The foundation links to ESMO resources alongside NCCN materials, with ESMO resources particularly useful for non-US patients and Spanish-speaking patients.
• Mayo ClinicsupportingStrategic or Co-development PartnerMayo Clinic is a participating institution in the Gallbladder Cancer Foundation's Genome Wide Association Study (GWAS), a research collaboration to identify genomic variants associated with gallbladder cancer risk. Dr. Mohamed Ali at Mayo Clinic serves as the study contact. Blood samples can be drawn at local facilities (no need to travel to Mayo Clinic), and study costs are covered or reimbursed.
• Caris Life SciencessupportingTechnology or IntegrationCaris Life Sciences performed comprehensive biomarker testing (tissue-based genomic profiling) for at least one documented patient, identifying MSI-High status and high tumor mutational burden that guided immunotherapy treatment decisions. The foundation references Caris as a biomarker testing option for patients.
• Foundation MedicinesupportingTechnology or IntegrationFoundation Medicine performed FoundationOne liquid biopsy testing for at least one documented patient, confirming MSI-High status and measuring tumor mutational burden from a blood draw. The foundation references FoundationOne Liquid Biopsy as a liquid biopsy option when tissue biopsy is not feasible.
• Ambry GeneticssupportingTechnology or IntegrationAmbry Genetics performed hereditary cancer genetic testing for at least one documented patient to rule out Lynch Syndrome and hereditary BRCA mutations. The testing confirmed no hereditary cancer syndrome, meaning the patient's family members did not need additional genetic testing.
• UCSF (University of California San Francisco)coreStrategic or Co-development PartnerUCSF GI medical oncologist Dr. John Gordan provides virtual consultations to gallbladder cancer patients referred through the foundation's network. Dr. Gordan has expertise in gallbladder cancer and cholangiocarcinoma. In documented cases, UCSF specialists have guided treatment plans for patients being managed locally, enabling access to expert care without travel. UCSF also conducted an ARM-GI clinical trial feasibility review for stereotactic body radiation therapy.
• Ohio State University (James Cancer Center)coreStrategic or Co-development PartnerThe James Cancer Center at Ohio State University serves as a treatment center for gallbladder cancer patients referred through the foundation's network. Dr. Ashish Manne, a GI medical oncologist at OSU with expertise in gallbladder cancer, manages ongoing patient treatment including durvalumab immunotherapy infusions. OSU's Destination Medicine program helps coordinate care transitions for out-of-state patients.
• Cholangiocarcinoma FoundationsupportingStrategic or Co-development PartnerThe Cholangiocarcinoma Foundation is referenced as a key resource for finding biliary tract cancer specialists (via their specialist map), clinical trials, educational videos, and support. Since cholangiocarcinoma and gallbladder cancer are both biliary tract cancers, the specialist networks and resources overlap significantly. The foundation also references Cholangiocarcinoma Foundation's YouTube channel for patient education.
• AMMF – The Cholangiocarcinoma Charity (UK)supportingStrategic or Co-development PartnerAMMF is the only UK charity dedicated to cholangiocarcinoma and the only UK organization supporting gallbladder cancer patients. It has been operating for over 20 years, working throughout the UK and Europe, and has access to healthcare professionals specializing in biliary tract cancers. The foundation connects UK and EU-based patients to AMMF for localized support and resources.
• ATUVIBI – Asociación de Tumores de Vías Biliares (Spain)supportingStrategic or Co-development PartnerATUVIBI is a nonprofit organization from Spain dedicated to improving the quality of life of individuals affected by biliary tract tumors. It supports patients and families, promotes scientific research, and raises awareness about the disease. The foundation connects Spanish-speaking patients to ATUVIBI for localized support.
• Cholangiocarcinoma Foundation AustraliasupportingStrategic or Co-development PartnerA patient-led cancer research and advocacy organization supporting patients in both Australia and New Zealand with cholangiocarcinoma and other bile-related cancers including gallbladder, liver, and pancreatic cancers. The foundation connects Australian and New Zealand patients to this organization for localized support and resources.
• Jarurat Care Foundation (India)supportingStrategic or Co-development PartnerJarurat Care Foundation is an Indian NGO founded in 2024 by Priyanka Joshi after her mother's cholangiocarcinoma diagnosis, with a mission to support and empower cancer patients and families in India with GI cancer, biliary tract cancer, and cholangiocarcinoma. It is backed by medical experts from MD Anderson Cancer Center and MGUMST Jaipur. The foundation connects Indian patients to Jarurat Care for localized support, with Dr. Milind Javle (MD Anderson) and Dr. V.K. Kapoor (MGUMST) serving on their expert panel.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cholangiocarcinoma Foundation: Largest US nonprofit dedicated to biliary tract cancer (cholangiocarcinoma). Most directly comparable peer: shares biliary tract cancer focus, patient support, research funding, and educational resources — and was the explicit inspiration for the Gallbladder Cancer Foundation.

Regional players

• AMMF – The Cholangiocarcinoma Charity: The only UK charity dedicated to cholangiocarcinoma and biliary tract cancers including gallbladder cancer. Operates in the UK and Europe with comparable patient support, awareness, and research funding activities.
• Cholangiocarcinoma Foundation Australia: Patient-led advocacy organization serving Australia and New Zealand with cholangiocarcinoma and other biliary-related cancers including gallbladder. Closely comparable model and disease focus.
• Jarurat Care Foundation: Indian NGO founded in 2024 supporting GI cancer, biliary tract cancer, and cholangiocarcinoma patients in India. Comparable emerging-market patient-support model with international medical advisory board.
• ATUVIBI – Asociación de Tumores de Vías Biliares: Spanish nonprofit dedicated to biliary tract tumors, supporting Spanish-speaking patients and families and promoting research. Directly comparable disease focus with regional/linguistic specialization.

Broad incumbents

• Pancreatic Cancer Action Network (PanCAN): Large US nonprofit dedicated to pancreatic cancer — a related but distinct GI cancer. Comparable patient-services and research-funding operating model at much greater scale, with adjacent anatomical/disease area.
• National Organization for Rare Disorders (NORD): US umbrella organization supporting all rare-disease patients including rare cancers. Provides advocacy, research grants, and patient resources at scale; relevant as an ecosystem umbrella rather than a direct competitor.

Emerging players

• Liver Cancer Connect / Blue Faery: Patient advocacy organization focused on hepatocellular carcinoma. Smaller-scale patient-advocacy nonprofit model comparable to the Gallbladder Cancer Foundation's positioning, though in a different (though adjacent) GI cancer.

Others

• The Assistance Fund: Independent copay assistance nonprofit that operates the biliary tract cancer fund the Gallbladder Cancer Foundation refers patients to. Ecosystem partner and functional complement in patient financial support.
• PAN Foundation: National copay assistance foundation providing financial aid for underinsured patients, including biliary tract cancer. Referenced as a resource by the foundation; comparable model of independent charitable assistance for treatment costs.

Market position

Strengths5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/cureGBC
• YouTubeyoutube.com/channel/UCyEQOXw88CLOg5loBqC5m0A
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/gallbladder-cancer-foundation
• Instagraminstagram.com/gallbladdercancer

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gallbladder Cancer Foundation